Gln/Gln
Arg/Arg
Gln/Gln
Arg/Gly
Gln/Gln
Gly/Gly
Gln/Glu
Arg/Arg
Gln/Glu
Arg/Gly
Gln/Glu
Gly/Gly
Glu/Glu
Arg/Gly
Glu/Glu
Gly/Gly
Participants 11 15 7 3 32 18 5 12
Male 9(81.82%) 14(93.33%) 7(100%) 3(100%) 27(84.38%) 13(72.22%) 5(100%) 10(83.33%)
AsthmaStage
1 3(27.27%) 2(13.13%) 0 0 5(15.63%) 1(5.56%) 0 2(16.67%)
2 2(18.18%) 2(13.13%) 2(28.57%) 0 6(18.75%) 8(44.44%) 3(60%) 2(16.67%)
3 5(45.45%) 8(53.33%) 4(57.14%) 1(33.33%) 16(50%) 7(38.39%) 1(20%) 5(41.67%)
4 1(9.09%) 3(20%) 1(14.29%) 2(66.67%) 5(15.63%) 2(11.11%) 1(20%) 3(25%)
COPDStage                
1 4(36.36%) 4(26.67%) 0 0 9(28.13%) 6(33.33%) 2(40%) 3(25%)
2 3(27.27%) 6(40%) 4(57.14%) 0 14(43.75%) 6(33.33%) 1(20%) 5(41.67%)
3 3(27.27%) 4(26.67%) 2(28.57%) 2(66.67%) 6(18.75%) 5(27.78%) 1(20%) 2(16.67%)
4 1(9.09%) 1(6.67%) 1(14.29%) 1(33.33%) 3(9.38%) 1(5.56%) 1(20%) 2(16.67%)
Exacerbation                
0 5(45.45%) 8(53.33%) 0 0 15(46.88%) 3(16.67%) 2(40%) 5(41.67%)
1 3(27.27%) 3(20%) 5(71.43%) 2(66.67%) 11(34.38%) 13(72.22%) 1(20%) 3(25%)
2 1(9.09%) 2(13.33%) 2(28.57%) 0 4(12.50%) 1(5.56%) 1(20%) 1(8.33%)
3 0 1(6.67%) 0 0 0 0 0 2(16.67%)
4 1(9.09%) 0 0 1(33.33%) 1(3.13%) 1(5.56%) 0 0
5 0 0 0 0 1(3.13%) 0 0 0
6 1(9.09%) 0 0 0 0 0 0 0
8 0 0 0 0 0 0 0 1(8.33%)
12 0 1(6.67%) 0 0 0 0 1(20%) 0
OralSteroid                
0 5(45.45%) 8(53.33%) 1(14.29%) 0 16(50%) 4(22.22%) 2(40%) 5(41.67%)
1 3(27.27%) 3(20%) 4(57.14%) 2(66.67%) 12(37.5%) 11(61.11%) 1(20%) 3(25%)
2 1(9.09%) 2(13.13%) 1(14.29%) 0 2(6.25%) 2(11.11%) 1(20%) 1(8.33%)
3 2(18.18%) 0 0 0 0 0 0 2(16.67%)
4 0 0 1(14.29%) 0 1(3.13%) 1(5.56%) 0 0
5 0 1(6.67%) 0 1(33.33%) 1(3.13%) 0 0 0
8 0 0 0 0 0 0 0 1(8.33%)
13 0 0 0 0 0 0 1(20%) 0
14 0 1(6.67%) 0 0 0 0 0 0
Table 4: Statistical summary of the participants, Asthma stage, COPD stage, Exacerbation and Oral Steroid use by genotype (Arg16Gly and Gln27Glu combination).
Goto home»